ARS Pharmaceuticals (SPRY) Cash & Equivalents (2020 - 2026)

ARS Pharmaceuticals has disclosed Cash & Equivalents across 7 years of filings, most recently posting $24.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $24.3 million, down 38.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.3 million (down 38.99% YoY), and the FY2025 annual result was $41.3 million, down 18.69% from the prior year.
• Cash & Equivalents came in at $24.3 million for Q1 2026 at ARS Pharmaceuticals, down from $41.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $234.0 million in Q1 2022 to a low of $24.3 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $59.6 million (2025), against an average of $94.4 million.
• Across the five-year window, Cash & Equivalents soared 250.5% in 2022 and sank 70.21% in 2023, its largest moves.
• ARS Pharmaceuticals' Cash & Equivalents stood at $210.5 million in 2022, then plunged by 66.29% to $71.0 million in 2023, then fell by 28.4% to $50.8 million in 2024, then dropped by 18.69% to $41.3 million in 2025, then slumped by 41.14% to $24.3 million in 2026.
• The last three Cash & Equivalents figures came in at $24.3 million (Q1 2026), $41.3 million (Q4 2025), and $59.6 million (Q3 2025), per Business Quant data.